Monopar Therapeutics financial data

Symbol
MNPR on Nasdaq
Industry
Pharmaceutical Preparations
Location
1000 Skokie Blvd Suite 350, Wilmette, IL
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 416 % -44.5%
Debt-to-equity 24.3 % -8.51%
Return On Equity -111 % -9.65%
Return On Assets -89 % -11.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 17.6M shares +24.3%
Common Stock, Shares, Outstanding 17.6M shares +26.6%
Entity Public Float 4.61M USD -53.9%
Common Stock, Value, Issued 17.6K USD +26.7%
Weighted Average Number of Shares Outstanding, Basic 17.5M shares +30.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 4.45M USD -37.2%
General and Administrative Expense 3.04M USD -1.47%
Operating Income (Loss) -7.49M USD +26.3%
Net Income (Loss) Attributable to Parent -7.12M USD +28.3%
Earnings Per Share, Basic -0.46 USD/shares +37.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.12M USD -15.2%
Cash, Cash Equivalents, and Short-term Investments 10.4M USD
Other Assets, Current 61K USD -44.5%
Assets, Current 7.18M USD -30.3%
Operating Lease, Right-of-Use Asset 0 USD -100%
Assets 7.18M USD -30.6%
Liabilities, Current 1.76M USD -43.8%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 1.09M USD -56.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 8.26K USD +14.3%
Retained Earnings (Accumulated Deficit) -63.6M USD -12.6%
Stockholders' Equity Attributable to Parent 6.09M USD -22.3%
Liabilities and Equity 7.18M USD -30.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.66M USD +27.1%
Net Cash Provided by (Used in) Financing Activities 3.18M USD +295%
Net Cash Provided by (Used in) Investing Activities -983K USD +0.01%
Common Stock, Shares Authorized 40M shares 0%
Common Stock, Shares, Issued 17.6M shares +26.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 541K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.73M USD -67.9%
Deferred Tax Assets, Valuation Allowance 13.3M USD +19.1%
Cash and Cash Equivalents, Period Increase (Decrease) -2.48M USD -128%
Deferred Tax Assets, Gross 13.3M USD +19.1%
Operating Lease, Liability 8.41K USD -85.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -7.12M USD +42.5%
Lessee, Operating Lease, Liability, to be Paid 8.48K USD -85.7%
Operating Lease, Liability, Current 47.8K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 8.48K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 8.48K USD -83.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 68 USD -97.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 8.48K USD
Deferred Tax Assets, Operating Loss Carryforwards 3.87M USD +9.1%
Unrecognized Tax Benefits 336K USD +4.56%
Additional Paid in Capital 63.1M USD +4.01%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 476K USD -4.72%